nach oben

Journal of Mammary Gland Biology and Neoplasia

Erschienen in:

01.07.2014

Breast Cancer Stem Cells and the Immune System: Promotion, Evasion and Therapy

verfasst von: Sarah T. Boyle, Marina Kochetkova

Erschienen in: Journal of Mammary Gland Biology and Neoplasia | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Cancer stem cells are believed to be a subset of heterogeneous tumour cells responsible for tumour initiation, growth, local invasion, and metastasis. In breast cancer, numerous factors have been implicated in regulation of cancer stem cells, but there is still a paucity of information regarding precise molecular and cellular mechanisms guiding their pathobiology. Components of both the adaptive and the innate immune system have been shown to play a crucial role in supporting breast cancer growth and spread, and recently some immune mediators, both molecules and cells, have been reported to influence breast cancer stem cell biology. This review summarises a small, pioneering body of evidence for the potentially important function of the “immuniche” in maintaining and supporting breast cancer stem cells.

Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011;17(3):313–9.PubMedCrossRef

Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med. 1997;3(7):730–7.PubMedCrossRef

Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012;10(6):717–28.PubMedCrossRef

Malanchi I et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature. 2012;481(7379):85–9.CrossRef

Bouras T et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell. 2008;3(4):429–41.PubMedCrossRef

Liu S et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006;66(12):6063–71.PubMedCrossRef

Wang, Y., et al., Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene, 2010.

van Amerongen R, Bowman AN, Nusse R. Developmental stage and time dictate the fate of Wnt/beta-catenin-responsive stem cells in the mammary gland. Cell Stem Cell. 2012;11(3):387–400.PubMedCrossRef

Karamboulas C, Ailles L. Developmental signaling pathways in cancer stem cells of solid tumors. Biochim Biophys Acta. 2013;1830(2):2481–95.PubMedCrossRef

10.

Alison, M.R., S.M. Lim, and L.J. Nicholson, Cancer stem cells: problems for therapy? J Pathol, 2010.

11.

Al-Hajj M et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100(7):3983–8.PubMedCentralPubMedCrossRef

12.

Shackleton M et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439(7072):84–8.PubMedCrossRef

13.

Stingl J et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439(7079):993–7.PubMed

14.

Patrawala L et al. Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. Cancer Res. 2005;65(14):6207–19.PubMedCrossRef

15.

Ginestier C et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.PubMedCentralPubMedCrossRef

16.

Dontu G et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253–70.PubMedCentralPubMedCrossRef

17.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74.PubMedCrossRef

18.

Aspord C et al. Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J Exp Med. 2007;204(5):1037–47.PubMedCentralPubMedCrossRef

19.

DeNardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9(4):212.PubMedCentralPubMedCrossRef

20.

Olkhanud PB et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res. 2011;71(10):3505–15.PubMedCentralPubMedCrossRef

21.

Liyanage UK et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169(5):2756–61.PubMedCrossRef

22.

Gobert M et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009;69(5):2000–9.PubMedCrossRef

23.

Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226(2):148–57.PubMedCrossRef

24.

Bombonati A, Sgroi DC. The molecular pathology of breast cancer progression. J Pathol. 2011;223(2):307–17.PubMedCentralPubMedCrossRef

25.

de la Cruz-Merino L et al. New insights into the role of the immune microenvironment in breast carcinoma. Clin Dev Immunol. 2013;2013:785317.PubMedCentralPubMed

26.

Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36(5):705–16.PubMedCentralPubMedCrossRef

27.

Qian BZ et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–5.PubMedCentralPubMedCrossRef

28.

Nannuru KC et al. Role of chemokine receptor CXCR2 expression in mammary tumor growth, angiogenesis and metastasis. J Carcinog. 2011;10:40.PubMedCentralPubMedCrossRef

29.

Zhang Y et al. A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells. Cell Res. 2013;23(3):394–408.PubMedCentralPubMedCrossRef

30.

Cabioglu N et al. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res. 2005;11(16):5686–93.PubMedCrossRef

31.

Russo RC et al. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases. Expert Rev Clin Immunol. 2014;10(5):593–619.PubMedCrossRef

32.

Charafe-Jauffret E et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009;69(4):1302–13.PubMedCentralPubMedCrossRef

33.

Ginestier C et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest. 2010;120(2):485–97.PubMedCentralPubMedCrossRef

34.

Acharyya S et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165–78.PubMedCentralPubMedCrossRef

35.

Singh S et al. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin Cancer Res. 2009;15(7):2380–6.PubMedCrossRef

36.

Korkaya H et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell. 2012;47(4):570–84.PubMedCentralPubMedCrossRef

37.

Marotta LL et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(−) stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121(7):2723–35.PubMedCentralPubMedCrossRef

38.

Liu S et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011;71(2):614–24.PubMedCentralPubMedCrossRef

39.

Chapman RW et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther. 2009;121(1):55–68.PubMedCrossRef

40.

Kodama J et al. Association of CXCR4 and CCR7 chemokine receptor expression and lymph node metastasis in human cervical cancer. Ann Oncol. 2007;18(1):70–6.PubMedCrossRef

41.

Kochetkova M, Kumar S, McColl SR. Chemokine receptors CXCR4 and CCR7 promote metastasis by preventing anoikis in cancer cells. Cell Death Differ. 2009;16(5):664–73.PubMedCrossRef

42.

Dubrovska A et al. CXCR4 activation maintains a stem cell population in tamoxifen-resistant breast cancer cells through AhR signalling. Br J Cancer. 2012;107(1):43–52.PubMedCentralPubMedCrossRef

43.

Sheridan C et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5):R59.PubMedCentralPubMedCrossRef

44.

Huang M et al. Breast cancer stromal fibroblasts promote the generation of CD44 + CD24- cells through SDF-1/CXCR4 interaction. J Exp Clin Cancer Res. 2010;29:80.PubMedCentralPubMedCrossRef

45.

Cronin PA, Wang JH, Redmond HP. Hypoxia increases the metastatic ability of breast cancer cells via upregulation of CXCR4. BMC Cancer. 2010;10:225.PubMedCentralPubMedCrossRef

46.

Smith MC et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64(23):8604–12.PubMedCrossRef

47.

Asiedu MK et al. TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res. 2011;71(13):4707–19.PubMedCentralPubMedCrossRef

48.

Luker KE et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene. 2012;31(45):4750–8.PubMedCentralPubMedCrossRef

49.

Yoshimura T et al. Monocyte chemoattractant protein-1/CCL2 produced by stromal cells promotes lung metastasis of 4 T1 murine breast cancer cells. PLoS One. 2013;8(3):e58791.PubMedCentralPubMedCrossRef

50.

Velasco-Velazquez M et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res. 2012;72(15):3839–50.PubMedCrossRef

51.

Tsuyada A et al. CCL2 mediates cross-talk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells. Cancer Res. 2012;72(11):2768–79.PubMedCentralPubMedCrossRef

52.

Carr MW et al. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci U S A. 1994;91(9):3652–6.PubMedCentralPubMedCrossRef

53.

Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell. 2009;139(4):693–706.PubMedCentralPubMedCrossRef

54.

Sansone P et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest. 2007;117(12):3988–4002.PubMedCentralPubMedCrossRef

55.

Iliopoulos D et al. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011;108(4):1397–402.PubMedCentralPubMedCrossRef

56.

Visvader JE. Cells of origin in cancer. Nature. 2011;469(7330):314–22.PubMedCrossRef

57.

Marotta, L.L., et al., The JAK2/STAT3 signaling pathway is required for growth of CD44 + CD24- stem cell-like breast cancer cells in human tumors. J Clin Invest, 2011. 121(7).

58.

Ansieau S. EMT in breast cancer stem cell generation. Cancer Lett. 2013;338(1):63–8.PubMedCrossRef

59.

Xie G et al. IL-6-induced epithelial-mesenchymal transition promotes the generation of breast cancer stem-like cells analogous to mammosphere cultures. Int J Oncol. 2012;40(4):1171–9.PubMedCentralPubMed

60.

Sullivan NJ et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene. 2009;28(33):2940–7.PubMedCrossRef

61.

Anderson DM et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390(6656):175–9.PubMedCrossRef

62.

Page G, Miossec P. RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum. 2005;52(8):2307–12.PubMedCrossRef

63.

Palafox M et al. RANK induces epithelial-mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis. Cancer Res. 2012;72(11):2879–88.PubMedCrossRef

64.

Pellegrini P et al. Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. Stem Cells. 2013;31(9):1954–65.PubMedCrossRef

65.

Thomas E et al. Receptor activator of NF-kappaB ligand promotes proliferation of a putative mammary stem cell unique to the lactating epithelium. Stem Cells. 2012;30(6):1255–64.PubMedCrossRef

66.

Schramek D et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98–102.PubMedCentralPubMedCrossRef

67.

Arwert EN, Hoste E, Watt FM. Epithelial stem cells, wound healing and cancer. Nat Rev Cancer. 2012;12(3):170–80.PubMedCrossRef

68.

Spike BT et al. A mammary stem cell population identified and characterized in late embryogenesis reveals similarities to human breast cancer. Cell Stem Cell. 2012;10(2):183–97.PubMedCentralPubMedCrossRef

69.

Asselin-Labat ML et al. Control of mammary stem cell function by steroid hormone signalling. Nature. 2010;465(7299):798–802.PubMedCrossRef

70.

Joshi PA et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465(7299):803–7.PubMedCrossRef

71.

Chin AR, Wang SE. Cytokines driving breast cancer stemness. Mol Cell Endocrinol. 2014;382(1):598–602.PubMedCrossRef

72.

Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815–22.PubMedCrossRef

73.

Sotiropoulou PA et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24(1):74–85.PubMedCrossRef

74.

Karnoub AE et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–63.PubMedCrossRef

75.

Dwyer RM et al. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 2007;13(17):5020–7.PubMedCrossRef

76.

Migneco G et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle. 2010;9(12):2412–22.PubMedCrossRef

77.

Liao D et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4 T1 murine breast cancer model. PLoS One. 2009;4(11):e7965.PubMedCentralPubMedCrossRef

78.

Orimo A et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.PubMedCrossRef

79.

Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71–8.PubMedCrossRef

80.

Chen J et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19(4):541–55.PubMedCentralPubMedCrossRef

81.

Okuda H et al. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res. 2012;72(2):537–47.PubMedCentralPubMedCrossRef

82.

Jinushi M et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A. 2011;108(30):12425–30.PubMedCentralPubMedCrossRef

83.

Hong CC et al. Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat. 2013;139(2):477–88.PubMedCentralPubMedCrossRef

84.

Liu F et al. CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645–55.PubMedCrossRef

85.

Seo AN et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109(10):2705–13.PubMedCrossRef

86.

Benevides L et al. Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor. Eur J Immunol. 2013;43(6):1518–28.PubMedCrossRef

87.

Santisteban M et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009;69(7):2887–95.PubMedCentralPubMedCrossRef

88.

Holzel M, Bovier A, Tuting T. Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer. 2013;13(5):365–76.PubMedCrossRef

89.

Reim F et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res. 2009;69(20):8058–66.PubMedCrossRef

90.

Knutson KL et al. Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol. 2006;177(3):1526–33.PubMedCrossRef

91.

Kawasaki BT et al. Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun. 2007;364(4):778–82.PubMedCentralPubMedCrossRef

92.

Wright SE. Immunotherapy of breast cancer. Expert Opin Biol Ther. 2012;12(4):479–90.PubMedCrossRef

93.

Wang LX, Plautz GE. T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors. Breast Cancer Res Treat. 2012;134(1):61–70.PubMedCentralPubMedCrossRef

94.

Mine T et al. Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother. 2009;58(8):1185–94.PubMedCentralPubMedCrossRef

95.

Ning N et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72(7):1853–64.PubMedCentralPubMedCrossRef

96.

Karyampudi, L., et al., Accumulation of Memory Precursor CD8 T Cells in Regressing Tumors Following Combination Therapy with Vaccine and Anti-PD-1 Antibody. Cancer Res, 2014.

Titel: Breast Cancer Stem Cells and the Immune System: Promotion, Evasion and Therapy
verfasst von: Sarah T. Boyle
Marina Kochetkova
Publikationsdatum: 01.07.2014
Verlag: Springer US
Erschienen in: Journal of Mammary Gland Biology and Neoplasia / Ausgabe 2/2014
Print ISSN: 1083-3021
Elektronische ISSN: 1573-7039
DOI: https://doi.org/10.1007/s10911-014-9323-y

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Breast Cancer Stem Cells and the Immune System: Promotion, Evasion and Therapy

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Stromal Fibroblasts and the Immune Microenvironment: Partners in Mammary Gland Biology and Pathology?

Preface

Cytokine Networks That Mediate Epithelial Cell-Macrophage Crosstalk in the Mammary Gland: Implications for Development and Cancer

CSF-1R Signaling in Health and Disease: A Focus on the Mammary Gland

Impact of Obesity on Mammary Gland Inflammation and Local Estrogen Production

Inflammatory Mediators in Mastitis and Lactation Insufficiency

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie